


PHARMACEUTICAL 2020

Evofem Biosciences Inc. Rank 351 of 362





PHARMACEUTICAL 2020

Evofem Biosciences Inc. Rank 351 of 362

The relative strengths and weaknesses of Evofem Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evofem Biosciences Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 112% points. The greatest weakness of Evofem Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 871% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,503%, being 1,200% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	26,421
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,659
Liabilities, Non-Current	0
Other Assets	1,480
Other Compr. Net Income	0
Other Expenses	4.0
Other Liabilities	0
Other Net Income	-27,287
Property and Equipment	394
Research and Development	22,230
Revenues	0
Selling, General and Administrative Expense	30,512

Output Variable	Value in 1000 USD
Assets	28,295
Liabilities	12,659
Expenses	52,746
Stockholders Equity	15,636
Net Income	-80,033
Comprehensive Net Income	-80,033
Economic Capital Ratio	-1,503%